Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
1. A compound having the following formula:
a pharmaceutical acceptable salt thereof, or a deuterated derivative of any of the foregoing.
2. A pharmaceutical composition comprising the compound, pharmaceutically acceptable salt, or deuterated derivative of claim 1 , a pharmaceutically acceptable carrier and optionally one or more of:
(a) Compound II:
a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; and
(b) Compound III:
a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
3. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition according to claim 2 .
4. A compound of the formula:
in the form of a pharmaceutically acceptable salt.
5. A compound having the following formula:
6. A pharmaceutical composition comprising the compound of claim 1 .
7. A pharmaceutical composition comprising the compound of claim 4 .
8. A pharmaceutical composition comprising the compound of claim 5 .
9. A pharmaceutical composition comprising a compound having the following formula:
or a pharmaceutically acceptable salt thereof; a pharmaceutically acceptable carrier; and optionally one or more of:
(a) Compound II:
a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; and
(b) Compound III:
a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
10. The pharmaceutical composition of claim 9 , wherein the compound having the following formula:
is in the form of a pharmaceutically acceptable salt.
11. A method of treating cystic fibrosis comprising administering to a patient in need thereof the compound according to claim 1 .
12. A method of treating cystic fibrosis comprising administering to a patient in need thereof the compound according to claim 4 .
13. A method of treating cystic fibrosis comprising administering to a patient in need thereof the compound according to claim 5 .
14. A method of treating cystic fibrosis comprising administering to a patient in need thereof the pharmaceutical composition according to claim 6 .
15. A method of treating cystic fibrosis comprising administering to a patient in need thereof the pharmaceutical composition according to claim 7 .
16. A method of treating cystic fibrosis comprising administering to a patient in need thereof the pharmaceutical composition according to claim 8 .
17. A method of treating cystic fibrosis comprising administering to a patient in need thereof the pharmaceutical composition according to claim 9 .
18. A method of treating cystic fibrosis comprising administering to a patient in need thereof the pharmaceutical composition according to claim 10 .